News
We send the latest information from SMC Laboratories.
Terns Pharmaceuticals Inc. announced that initiation of patient dosing in the LIFT study, a phase 2A clinical trial of TERN-101 in development for NASH
Terns Pharmaceuticals Inc. (USA and Shanghai) announced on 23 July, 2020, the initiation of patient dosing in …
NIDDK's publication in Purinergic Signaling
SMC announces that NIDDK (MD) has published the results of a study using the STAMTM mouse model in Purinergic …
Genfit announced that it will discontinue the Phase 3 NASH study and concentrate on the developmento of PBC therapeutics.
Genfit (France) announced on July 22, 2020, that it will discontinue Elafibranor's Phase 3 NASH clinical …
Merck's publication in Cell Reports Medicine
SMC announces that Merck & Co., Inc. (NJ) has published the results of a study using STAMTM mouse model in…
DURECT has published a news release regarding positive topline data from phase 1b study of DUR-928 in NASH
DURECT CORPORATION (USA) announced on May 26, 2020, that positive topline data was obtained in serum liver enz…
FDA rejects Intercept Pharma's drug for NASH for now
Intercept Pharmaceuticals, Inc. (USA) announced that it has received a notification from the FDA that it will …
Hepion pharma has publshed a pres releaes regarding the CRV431 efficacy evaluation study for kidney fibrosis we have provied.
Hepion pharma, which is our client, has announced the results of pharmacology study using a UUO mouse model. &…
Continuum Biosciences’s publication in Journal of Medicinal Chemistry
SMC announces that Continuum Biosciences, Pty Ltd. has published the results of a study using STAM model on Jo…
Sabinsa Corporation’s publication in Scientific Reports
SMC announces that Sabinsa Corporation has published the results of a study using STAM model in Scientific Rep…
Juntendo University’s publication on European Radiology Experimental
SMC announces that Juntendo University has published the results of a study using STAM™ model in Europea…